##### 



EXHIBIT 10.57   ***Text Omitted and Filed SeparatelyConfidential Treatment
RequestedUnder 17 C.F.R. §§ 200.80(b)(4)
and240.24b-2(b)(1)
 Development Collaboration and Supply Agreement
 between
 Medarex, Inc.
 and




---



##### 



DEVELOPMENT COLLABORATION AND SUPPLY AGREEMENT
 ThisDevelopment Collaboration and Supply Agreement Effective Date), Medarex, Inc., (Medarex), IDM S.A., (IDM).
 RECITALS
 Whereas,
 Whereas,
 Whereas,
 Whereas, Technology Access Agreement)
 Whereas,
 Whereas,
 Whereas,
 Now, Therefore,
 *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§200.80(b)(4)and240.24b-2(b)(1)
 2




---



##### 



1. Definitions
  1.1 Affiliate
 Antibody
 1.3 Batch
 BLA (MAA).
 1.5 Cell-based Vaccine in vitro, Subcomponent).
 3




---



##### 



1.6 cGMP
 1.7 Confidential Information
 1.8 Contract Year
 1.9 DMF
 1.10 FDA,
 1.11 Field
 1.12 IND
 1.13 Information
 1.14 Invention,
 1.15 Marketing Authorization Approval
 1.16 Medarex Development Program
 1.17 Net Revenues (Consideration)
 4




---



##### 



1.22
   5




---



##### 



1.26 Technology Access Agreement
 2. Development Collaboration
 2.1 Scope of the Development Collaboration.
 Product Development Program)
 Medarex Development Program).
 2.2 Collaboration Governance.
 (a) Establishment of the Steering Committee. Steering Committee),
 (b) Tasks of the Steering Committee. Product Development
 6




---



##### 



Plan);
 (c) Procedures and Decisions of the Steering Committee.
 (i)
 (ii)
 (iii)
 2.3 Process Development Program.
 7




---



##### 



2.4 Product Development Program.
  Anti-CTLA-4 Costs)
  2.5 Exchange of Information
 (a)
  *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§200.80(b)(4)and240.24b-2(b)(1)
 8




---



##### 



2.6 Regulatory Filings and Approvals.
 (a) Manufacturing Approvals.
 (b) Marketing Authorization Approvals for the Antibody.
 (i)
 (ii)
 (iii)
 (c) Marketing Authorization Approvals for the Product.
 (i) Product BLA).
 9




---



##### 



(ii)
 2.7 Limited Use
 (a)
   2.8 Supply of Antibody for Commercial Use.
 (a)
  10




---



##### 



(c)
 3. Forecasts; Orders; Deliveries
 3.1 Forecasts.
 3.2 Orders.
   11




---



##### 



3.3 Deliveries.
 4. Price; Payments
 4.1 Price.
 4.2 Method of Payments.
 5. Product Warranty; Acceptance and Rejection
 5.1 Limited Warranty.
 5.2 Delivery Documentation; Testing.
 (a) QC
Sample
 (b)
 *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§200.80(b)(4)and240.24b-2(b)(1)
 12




---



##### 



5.3 Acceptance and Rejection.
    5.4 Remedy for Breach of Limited Warranty.
 6. Regulatory Matters
 6.1 Changes to Specifications and Manufacturing Process.
 13




---



##### 



6.2 Regulatory Support for Clinical Trial Applications.
  6.3 Regulatory Support for BLA and MAA
 14




---



##### 



6.4 cGMP Compliance and QA Audits.
 6.5 Adverse Event Reporting.
    7 Intellectual Property
 7.1 Inventorship.
 7.2 Sole Ownership.
  Sole Invention Combination Invention
 7.3 Joint Ownership.
 15




---



##### 



Joint Invention), (Joint Patents).
   7.4 Grant of Rights.
 (a) Grant of Rights to IDM.
 (i) Rights of Use and Reference.
 (ii) License to Cell-based Vaccine Inventions.
 *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§200.80(b)(4)and240.24b-2(b)(1)
 16




---



##### 



(iii) Consideration.
 (b) Grant of Rights to Medarex.
 (i) Rights of Use and Reference.
 (ii) License to Antibody Inventions.
 (iii) Consideration.
 (1)
 (2)
 *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§200.80(b)(4)and240.24b-2(b)(1)
 17




---



##### 



Sublicense of IDM's Sole Patents
    
    Sublicense of Joint PatentsNaked Sublicense
    
    [...***...]
    
    [...***...]Combined Sublicense
    
    [...***...]
    
    [...***...]
  7.5 Patent Prosecution and Enforcement for Joint Patents.
 (a) Steering Committee. Designated
Party)
 (b) Designated Party to Control.
 (c) Invoicing.
 *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§200.80(b)(4)and240.24b-2(b)(1)
 18




---



##### 



(d) Cooperation.
 (e) Updates on Developments.
 (f) Designated Party Abandonment.
 (g) Infringement of Joint Patents.
 (i)
 (ii)
 (iii)
 (iv)
 19




---



##### 



7.6 Patent Prosecution and Enforcement for Solely Owned Intellectual Property.
  Licensed Sole Patent),
    20




---



##### 



7.7 Patent Prosecution and Enforcement for Combination Inventions.
  mutatis mutandis
 7.8 Antibody Intellectual Property.
 7.9 Infringement of Third Party Rights.
   21




---



##### 



8. Representations And Warranties; Limitation of Liability
 8.1 Mutual Representations and Warranties.
     8.2 Limitation of Liability.
   22




---



##### 



9. Indemnification
 9.1 By Medarex. IDM Indemnitee) (Liabilities)
 9.2 By IDM. Medarex Indemnitee)
 9.3 Procedure. Indemnitee) Indemnitor)
 10. Confidentiality; Publications; Publicity
 23




---



##### 



10.1 Obligation. Receiving
Party) Disclosing Party)
 10.2 Exclusions.
 10.3 Permitted Disclosures.
   10.4 Publications.
 24




---



##### 



10.5 Publicity.
 11. Duration, Expiration And Termination
 11.1 Term.
 11.2 Termination.
 11.3 Surviving Obligations.
 12. General Terms
 12.1 Governing Law, Jurisdiction, Venue and Service.
   25




---



##### 



12.2 Notices.
 If to Medarex:
    
    Medarex, Inc.707 State Road #206Princeton, NJ 08540_U.S.A.Attn: PresidentFax No.: (609) 430-2850With a copy to:
    
    Medarex, Inc.707 State Road #206Princeton, NJ 08540U.S.A.Attn: General CounselFax No.: (609) 430-2850IftoIDM:
    
    IDMS.A.172 rue de Charonne75011 Paris, FranceAttn: PresidentFax No.:+33 1 40 09 04 25With a copy to:
    
    IDM S.A,172 rue de Charonne75011 Paris, FranceAttn: Legal CounselFax No.:+33 1 40 09 04 25
 26




---



##### 



12.3 Nonassignability; Binding on Successors.
 (a) ab initio
  12.4 No Benefit to Third Parties.
 12.5 Relationship of the Parties.
 12.6 Force Majeure.
 27




---



##### 



12.7 Compliance with Laws; Export Controls.
   12.8 Severability.
 12.9 Waiver.
 12.10 Use of Name.
 12.11 Construction.
   28




---



##### 



12.12 Entire Agreement; Amendments.
 12.13 Counterparts.
 [Rest of page intentionally left blank]
 29




---



##### 



In Witness Whereof,
 Medarex, Inc.
    
    IDM S.A.BY:
    
    /s/ Ronald A. Pepin
    
    BY:
    
    /s/ Bernard C. BrigonnetPrint Name: Ronald A. Pepin
    
    Print Name: Bernard C. BrigonnetTitle: Senior Vice President
    
    Title: Executive Vice President andBusiness Development
    
    
    
    Chief Operating Officer
 30




---



##### 



Exhibit
 Indications
   *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§200.80(b)(4)and240.24b-2(b)(1)
 31




---



##### 



Exhibit
 Antibody Specifications and Test Methods
  32




---



##### 



MEDAREX
  [...***...]
    
    [...***...]
    
    [...***...][...***...]
    
    [...***...]
    
    [...***...][...***...]
    
    [...***...]
    
    [...***...][...***...]
    
    [...***...]
    
    [...***...][...***...]
    
    [...***...]
    
    [...***...][...***...]
    
    [...***...]
    
    [...***...][...***...]
    
    [...***...]
    
    [...***...][...***...]
    
    [...***...]
    
    [...***...][...***...]
    
    [...***...]
    
    [...***...][...***...]
    
    [...***...]
    
    [...***...][...***...]
    
    [...***...]
    
    [...***...][...***...]
    
    [...***...]
    
    [...***...][...***...]
    
    [...***...]
    
    [...***...][...***...]
    
    [...***...]
    
    [...***...]
 *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§200.80(b)(4)and240.24b-2(b)(1)
 33




---



##### 



Exhibit C
 Milestones
  Milestone Event
    
    Milestone Payment1.
    
    
    Upon approval of the first BLA, or equivalent in the United States
    
    [...***...]2.
    
    
    Upon approval of the first MAA, or equivalent in the European
Union
    
    [...***...]3.
    
    
    Upon approval of the first MAA, or equivalent in Japan
    
    [...***...]
   *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§200.80(b)(4)and240.24b-2(b)(1)
 34




---



##### 



Exhibit D
 Letter Agreement
  35




---



##### 



707 Slate Road
Princeton O854O-1437
609-430-2880 Fax: 609-430-2850  
            *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§200.80(b)(4)and240.24b-2(b)(1)
 36




---



##### 



37